- Home
- ENTA vs SLS Comparison
ENTA vs SLS Comparison
Compare ENTA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- SLS
- Stock Information
- Founded
- ENTA 1995
- SLS 2012
- Country
- ENTA United States
- SLS United States
- Employees
- ENTA N/A
- SLS N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- SLS Health Care
- Exchange
- ENTA Nasdaq
- SLS Nasdaq
- Market Cap
- ENTA 164.6M
- SLS 165.6M
- IPO Year
- ENTA 2013
- SLS N/A
- Fundamental
- Price
- ENTA $8.83
- SLS $1.91
- Analyst Decision
- ENTA Strong Buy
- SLS Strong Buy
- Analyst Count
- ENTA 4
- SLS 1
- Target Price
- ENTA $20.75
- SLS $7.00
- AVG Volume (30 Days)
- ENTA 173.1K
- SLS 1.8M
- Earning Date
- ENTA 08-11-2025
- SLS 08-12-2025
- Dividend Yield
- ENTA N/A
- SLS N/A
- EPS Growth
- ENTA N/A
- SLS N/A
- EPS
- ENTA N/A
- SLS N/A
- Revenue
- ENTA $64,806,000.00
- SLS N/A
- Revenue This Year
- ENTA N/A
- SLS N/A
- Revenue Next Year
- ENTA $4.05
- SLS N/A
- P/E Ratio
- ENTA N/A
- SLS N/A
- Revenue Growth
- ENTA N/A
- SLS N/A
- 52 Week Low
- ENTA $4.09
- SLS $0.77
- 52 Week High
- ENTA $13.43
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- ENTA 65.93
- SLS 60.77
- Support Level
- ENTA $6.45
- SLS $1.50
- Resistance Level
- ENTA $7.73
- SLS $1.77
- Average True Range (ATR)
- ENTA 0.55
- SLS 0.11
- MACD
- ENTA 0.17
- SLS 0.04
- Stochastic Oscillator
- ENTA 90.15
- SLS 97.62
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.